It is currently not possible for a human to live more than 200 years. The longest-lived person in recorded history was Jeanne Calment, who lived to the age of 122 years and 164 days. While it is theoretically possible that advances in medicine and technology could extend human lifespan, it is not known if it would be possible for a person to live beyond 200 years.
With the use and development of artificial intelligence (AI), the future of anti-aging is in a new era. Scientists are turning to machines that cannot experience age themselves.
How AI is changing the way we develop drugs Speed, accuracy, and precision are crucial in the field of drug development?
It takes a long time to develop a new drug and get it on the market. This is especially true for anti-aging treatments, which take a long time to show any results. The problem is that when a drug patent starts, it starts from the beginning of the pipeline, not when the drug is released to the public. If it takes more than 20 years to test a drug and see if it works, then we can’t make any money off of it.
Many companies are using AI to identify promising compounds for drugs. This can be done in several different ways.
Researchers at Atomwise wanted to know if any existing, FDA-approved medications could be useful for fighting Ebola. They found a likely target for intervention- a particular point on a viral coat protein that needs another protein to operate. They hoped that by blocking the receptor they could prevent the virus from entering cells. After training their model by asking how well a set of compounds fit the target receptor, they fed the algorithm new compounds and asked how well these fit. Out of 7000 compounds, they identified 17 promising compounds.
Numerate wanted to use a molecule that would fit the same receptor as ApoE4 to target Alzheimer’s disease. They used a process called scaffold hopping to generate molecular formulas for compounds that would fit the same receptor. This process took about 9 months and cost $1,000,000. Out of 10 million compounds, they found 10 that were patentable. 4 of those went on to pass in vivo studies.
Some companies use computers to learn how poisonous a drug might be. The computer looks at how poisonous different drugs are and what they are made of. Then it guesses how poisonous a new drug might be. This helps the company save money because they don’t have to test every new drug to see if it is poisonous.
BioAge Labs took a different approach to finding new drugs. They looked for biomarkers instead of using deep learning. Biomarkers are measurements that are highly predictive of aging outcomes. This allows you to evaluate the use of your intervention without waiting for the event you are trying to cause or avoid. For example, looking for treatments that reduce blood pressure is easier than looking for treatments that reduce heart attacks, because you’re able to get statistically significant results from a smaller sample size over a shorter period of time. This means that useless compounds are discarded sooner, and promising compounds are brought to the public faster.
Less than a year after he rocked the scientific world with his claim to have gene-edited twin babies, scientist He Jiankui is back. This time, he has set up a laboratory in Beijing Daxing district. Despite calls for a moratorium on gene editing following his previous announcement, it seems that Jiankui has not been deterred from continuing his research. In an interview with Chinese media outlet Xinhua, Jiankui said that he plans to use CRISPR-Cas9 technology to “eliminate genetic diseases in newborns.” While many are appalled by Jiankui’s actions, it is important to note that his research does have some potential benefits. However, until more is known about the safety and efficacy of gene editing, it is best to proceed with caution. Stay tuned for future developments!
At the end of 2019, He Jiankui was sentenced to 3 years in prison for the “gene editing” case. He was released from prison in the first half of this year.
Regarding his new news, He Jiankui also further updated the news: Attending the conference on rare diseases…
According to his personal statement, he will be engaged in scientific research on gene therapy for rare genetic diseases in this new laboratory located in Daxing, Beijing.
In recent years, the research on covid, mRNA technology has gradually matured, and molecular biology and information biology have entered a rapid development. but– Entering 2022, there seems to be a fog of silence in the longevity medicine community. Many big names have entered a state of contemplation. If you know the theory of the singularity, you know that on the eve of the singularity, the lotus leaves in the pond seem to be scattered, but exponential growth will make them cover the entire pond overnight. The singularity of immortality is that life is extended faster than time itself. That moment each year when medical biology can extend life expectancy by more than a year is the singularity of immortality. This is probably in theory that we can extend our lifespan indefinitely. Many people will ask, is there an end to this? no. Human lifespan is determined by genes, and there are infinite possibilities based on cracking. A full brain can increase brain capacity and become a big head man. The head is so large that it can edit genes to delete redundant memories. We gradually changed from the treatment of body organs to temporarily prolong lifespan, to changing genes to permanently prolong lifespan, and then changing genes to make them have the function of automatic rejuvenation. It’s just that these may not be available to ordinary people. Therefore, longevity medicine will gradually be filled with fog, and big coffees will slowly enter into contemplation.